ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Syngene Slates Ingredients Plant

by Jean-François Tremblay
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

Indian contract research firm Syngene is acquiring land in Mangalore to build a commercial-scale active pharmaceutical ingredients plant. In a statement to the Bombay Stock Exchange, Syngene’s parent, Biocon—India’s largest biotechnology firm—says Syngene has reserved 40 acres of land in an economic zone to produce APIs as well as advanced intermediates and agrochemicals for its clients. The move by Syngene, India’s largest contract research firm, mirrors that of Wuxi Apptec, China’s largest contract research firm, which is also expanding its custom manufacturing operations.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment